MigraineActive ingredient
Erenumab
CGRP receptor antibody1 FDA label read
Erenumab is sold as Aimovig, a monthly self-injected antibody for the preventive treatment of migraine in adults. Among the three antibodies in this category it stands apart by target: it binds the CGRP receptor, where Emgality and Ajovy bind the CGRP molecule itself.
Highlights of the labels
- Aimovig
- Preventive treatment of migrainecovers migraine
- Supply
- Prescription only
- Generic
- None approved
- Boxed warning
- None in these labels
Brands and what each one is approved for
One active ingredient can hold several separate FDA approvals. They are different documents with different approved uses, and mixing them up is the most common mistake made about these medications.
| Brand | What its label approves | Supply | Label version |
|---|---|---|---|
| AimovigAmgen, Inc | What its label approvesPreventive treatment of migraineCovers migraine | SupplyPrescription | Label version14 July 2026 |
How it works
Erenumab is a human monoclonal antibody that binds to the CGRP receptor and antagonizes its function - the receptor-side counterpart of the ligand-binding antibodies. It is injected under the skin of the abdomen, thigh or upper arm once monthly.
Mechanism of action, Aimovig label
Erenumab-aooe is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
What the FDA approved it for
The approved uses, as worded in the label.
- AIMOVIG is indicated for the preventive treatment of migraine in adults.
- AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.
Forms and strengths
The presentations and strengths listed in the label.
- AIMOVIG is a sterile, clear to opalescent, colorless to light yellow solution available as follows:
- Injection: 70 mg/mL in a single-dose prefilled SureClick ® autoinjector Injection: 140 mg/mL in a single-dose prefilled SureClick ® autoinjector Injection: 70 mg/mL in a single-dose prefilled syringe Injection: 140 mg/mL in a single-dose prefilled syringe Injection: 70 mg/mL solution in a single-dose prefilled SureClick ® autoinjector
- Injection: 70 mg/mL solution in a single-dose prefilled syringe
- Injection: 140 mg/mL solution in a single-dose prefilled syringe
How the label says it is taken
What the label states about administration. It is not a dosing instruction for any individual.
- For subcutaneous use only
- Recommended dosage is 70 mg once monthly; some patients may benefit from a dosage of 140 mg once monthly
- Administer in the abdomen, thigh, or upper arm subcutaneously
- See Dosage and Administration for important administration instructions
Most common adverse reactions
The adverse reactions the label reports as most common.
- most common adverse reactions in AIMOVIG clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation.
- most common adverse reactions (incidence ≥ 3% and more often than placebo) in the migraine studies were injection site reactions and constipation.
Warnings and precautions
The warnings and precautions section of the label.
- Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue administration of AIMOVIG and initiate appropriate therapy. Hypersensitivity reactions can occur within hours to more than one week after administration.
- Constipation with Serious Complications: Serious complications of constipation may occur.
- Hypertension: New-onset or worsening of pre-existing hypertension may occur.
- Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur.
Contraindications
Situations in which the label states the medication must not be used.
- AIMOVIG is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients.
- Reactions have included anaphylaxis and angioedema.
Pregnancy and breastfeeding
The opening of the pregnancy section of the label. The full section is longer and is in the source document.
Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AIMOVIG during pregnancy. Patients should be encouraged to enroll by calling 1-833-244-4083 or visiting https://www.genesispregnancyregistry.com/. Risk Summary There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women.
Generic or brand
There is no generic erenumab: it is a biologic approved under a biologics license application, and copies of biologics reach the market as biosimilars, under their own approvals.
The FDA label database lists no approved generic application for this ingredient.
What affects the cost
Aimovig is a brand biologic priced per monthly injection. What a person pays depends on insurance coverage. This site sells nothing and links to no sellers.
What pharmacies pay for it
These are acquisition costs: what pharmacies in the United States pay on average to buy the medication, published weekly by the Centers for Medicare and Medicaid Services. They are not retail prices and not what a person pays at the counter, which depends on insurance, pharmacy and discount programs. They are useful as an objective floor and for seeing how far a brand sits above its generic.
| Measured | Brand |
|---|---|
| per milliliter | Brand$753.41 (range $738.51 to $753.94, 68 listings) |
Median of 68 listings. Effective dates 2025-12-17 to 2026-08-19, file dated 2026-08-26.
Compared with other medications
What the labels do not do is compare one medication against another. These pages put two of them side by side.
Common questions
- What doses does the Aimovig label set?
- 70 mg once monthly, with a note that some patients may benefit from 140 mg once monthly. It is for subcutaneous use only.
- Is Aimovig the same kind of medicine as Emgality and Ajovy?
- All three are preventive antibodies against CGRP signaling, but Aimovig binds the receptor while Emgality and Ajovy bind the CGRP molecule. The labels also differ in scope: Ajovy covers pediatric patients and a quarterly option, Emgality covers episodic cluster headache, Aimovig covers preventive treatment of migraine in adults.
- Can Aimovig stop an attack in progress?
- Acute treatment is not among its indications; the label covers preventive treatment of migraine in adults.
Other medications under migraine
Whether each one carries an FDA approval for this use is marked on its page and in this list.
Sources
Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.
FDA prescribing information for Aimovig
Amgen, Inc. Label version 25, effective 14 July 2026.
Each stripe is one section of the label, each division in a stripe one entry in that section.
Page last updated 29 August 2026
Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.